2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD73

CD73

ecto-5′-nucleotidase, NT5E

CD73

Related Products

PDF 0.28 MB

CD73 (Ecto-5′-nucleotidase) is a 70-kD glycosylphosphatidyl inositol (GPI)-anchored cell surface protein encoded by the NT5E gene that plays a crucial role in switching on adenosinergic signaling. CD73 is an ectonucleotidase which catalyzes the terminal step in extracellular adenine nucleotide breakdown: the conversion of AMP to adenosine. Adenosine, which binds to a discrete family of cell surface receptors to initiate intracellular signaling cascades, has been shown to be anti-inflammatory and vasorelaxant.

CD73 has both enzymatic and non-enzymatic functions in cells: as a nucleotidase, CD73 catalyzes the hydrolysis of AMP into adenosine and phosphate, and CD73-generated adenosine plays an important role in tumor immunoescape; moreover, CD73 also functions as a signal and adhesive molecule that can regulate cell interaction with extracellular matrix components, such as laminin and fibronectin, to mediate the invasive and metastatic properties of cancers. Both the enzymatic and non-enzymatic functions of CD73 are involved in cancer-associated processes and are not completely independent of each other. There is ample evidence to show that CD73 is a key regulatory molecule in cancer development and is overexpressed in many cancers, including leukemia, glioblastoma, melanoma, ovarian cancer, esophageal cancer, prostate cancer and breast cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-125286
    AB-680
    		Inhibitor 99.71%
    AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.
    AB-680
  • HY-100747
    PSB-12379
    		Inhibitor 99.96%
    PSB-12379, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human).
    PSB-12379
  • HY-112502C
    MethADP triammonium
    		Inhibitor 99.90%
    MethADP (Adenosine 5'-(α,β-methylene)diphosphate) triammonium is a CD73 inhibitor. MethADP can be used for the research of ATP-adenosine pathway.
    MethADP triammonium
  • HY-P99039
    Oleclumab
    		Inhibitor 99.90%
    Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity.
    Oleclumab
  • HY-P99181
    Mupadolimab
    		Inhibitor 99.43%
    Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells.
    Mupadolimab
  • HY-P992442
    PM-1015
    		Inhibitor
    PM-1015 is a specific antibody targeting CD73. PM-1015 can be used for the research of advanced solid tumor.
    PM-1015
  • HY-186182
    PF-1010
    		Inhibitor
    PF-1010 is a CD73 inhibitor with an IC50 ranging from 101 to 1000 nM. PF-1010 blocks the interaction between CD73 protein and its substrate, and inhibits the enzymatic activity of CD73. PF-1010 is applicable to the research of cancer, infectious diseases, autoimmune diseases and neurodegenerative diseases.
    PF-1010
  • HY-183620
    PSB-24379
    		Inhibitor
    PSB-24379 is a CD39 inhibitor that potently inhibits human membrane-bound CD39 (Ki = 77.4 nM) and truncated soluble human CD39 (Ki = 23.1 nM). PSB-24379 reduces the level of ATP hydrolysis in melanoma and breast cancer cell membranes. PSB-24379 partially reverses ATP-mediated suppression of T cell activation and proliferation in a high-ATP environment. PSB-24379 can be used in research related to melanoma and breast cancer.
    PSB-24379
  • HY-P99169
    Uliledlimab
    		Inhibitor 99.35%
    Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer.
    Uliledlimab
  • HY-112502
    MethADP
    		Inhibitor 99.0%
    MethADP is a specific CD73 inhibitor.
    MethADP
  • HY-P990263
    Anti-Mouse CD73 Antibody (TY/23)
    		Inhibitor
    Anti-Mouse CD73 Antibody (TY/23) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD73. Anti-Mouse CD73 Antibody (TY/23) can neutralize CD73. Anti-Mouse CD73 Antibody (TY/23) can be used for the researches of cancer, infection and immunology, such as B16F10 tumor and murine cytomegalovirus infection.
    Anti-Mouse CD73 Antibody (TY/23)
  • HY-103695
    CD73-IN-1
    		Inhibitor 98.77%
    CD73-IN-1 is an inhibitor of CD73 which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.
    CD73-IN-1
  • HY-145334
    CD73-IN-5
    		Inhibitor 98.04%
    CD73-IN-5 is a potent and selective non-nucleotide small molecule inhibitor of CD73 (IC50 = 19 nM).
    CD73-IN-5
  • HY-131967
    CD73-IN-4
    		Inhibitor 99.35%
    CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor, with an IC50 of 2.6 nM for human CD73. CD73-IN-4 is potential for the research of cancer immunology.
    CD73-IN-4
  • HY-137246
    CD73-IN-3
    		Inhibitor 99.89%
    CD73-IN-3 is a potent CD73 inhibitor (IC50=7.3 nM in Calu6 human cell assay). CD73-IN-3, example 2 extracted from patent WO2019168744 A1, has the potential for cancer research.
    CD73-IN-3
  • HY-P99865
    Dresbuxelimab
    		98.00%
    Dresbuxelimab (AK-119) is an IgG-κ monoclonal antibody targeting CD73. The expression system is usually CHO (Chinese Hamster Ovary) cells.
    Dresbuxelimab
  • HY-136978
    OP-5244
    		Inhibitor 99.07%
    OP-5244 is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research.
    OP-5244
  • HY-P991009
    Mavrostobart
    		98.50%
    HY-P991009 is an NT5E-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Mavrostobart
  • HY-P990900
    Ansipastobart
    HY-P990900 is an NT5E-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096).
    Ansipastobart
  • HY-136978A
    OP-5244 sodium
    		Inhibitor 99.87%
    OP-5244 sodium is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 sodium reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research.
    OP-5244 sodium
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity